Bavarian Nordic A/S (BVNKF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Bavarian Nordic A/S (BVNKF) trades at $27.80 with AI Score 52/100 (Grade B). Bavarian Nordic A/S specializes in developing and commercializing life-saving vaccines. Market cap: $2.14B, Sector: Healthcare.
Price live · AI analysis from Jun 13, 2026Analyst Coverage for BVNKF: BVNKF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BVNKF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
BVNKF: 5/6 perspectives are bullish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Bavarian Nordic A/S (BVNKF) Healthcare & Pipeline Overview
Bavarian Nordic A/S is a biotechnology firm focused on developing innovative vaccines for infectious diseases, leveraging its expertise in non-replicating viral vectors to address global health challenges.
What Is the Investment Thesis for BVNKF?
Bavarian Nordic A/S presents a compelling investment thesis driven by its robust pipeline of vaccine candidates and strategic collaborations. The company has a market capitalization of approximately $2.35 billion and a P/E ratio of 11.98, indicating a potentially undervalued position in the biotechnology sector. Key growth catalysts include the anticipated approval and commercialization of its MVA-BN RSV vaccine, which targets a significant market with a high unmet need, as well as the ongoing Phase III trials for its smallpox vaccine. The company's profit margin of 19.8% and gross margin of 47.4% reflect operational efficiency and strong pricing power. However, investors may want to evaluate potential risks, including regulatory hurdles and competition from other vaccine developers. Overall, Bavarian Nordic’s focus on innovative vaccine solutions positions it well for future growth in a rapidly evolving healthcare landscape.
Based on FMP financials and quantitative analysis
BVNKF Key Highlights
- Market capitalization of $2.14B, indicating strong market presence in the biotechnology sector.
- P/E ratio of 11.98, suggesting potential undervaluation compared to industry peers.
- Profit margin of 19.8%, reflecting operational efficiency and effective cost management.
- Gross margin of 47.4%, exceeding industry averages and demonstrating strong pricing power.
- Diverse product portfolio addressing significant public health challenges, including smallpox, monkeypox, and Ebola.
Who Are BVNKF's Competitors?
BVNKF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| MRNA Moderna, Inc. | $81.80 | +2.56% | 33B | — |
| PFE Pfizer Inc. | $23.73 | -2.43% | $135.25B | 64 |
| NVAX Novavax, Inc. | $9.35 | -4.00% | $1.54B | — |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BVNKF's Key Strengths?
- Diverse product portfolio addressing critical public health needs.
- Strong clinical pipeline with multiple candidates in advanced stages of development.
- Established collaborations with reputable health organizations enhancing credibility.
What Are BVNKF's Weaknesses?
- Dependence on government contracts for a significant portion of revenue.
- Limited market presence compared to larger pharmaceutical companies.
- No dividend payments may deter income-focused investors.
What Could Drive BVNKF Stock Higher?
- Completion of Phase III trials for MVA-BN RSV, with potential market entry in 2027.
- Collaboration with AdaptVac to develop new vaccine candidates, enhancing R&D capabilities.
- Progress in clinical trials for TAEK-VAC, with potential for new oncology treatment options.
What Are the Key Risks for BVNKF?
- Regulatory hurdles that may delay product approvals.
- Competition from larger pharmaceutical companies with established vaccine portfolios.
- Dependence on government contracts for a significant portion of revenue.
What Are the Growth Opportunities for BVNKF?
- Growth opportunity 1: Bavarian Nordic is advancing its MVA-BN RSV vaccine, currently in Phase III clinical trials, targeting a market with an estimated value of $6 billion. As respiratory syncytial virus remains a leading cause of hospitalization in infants and the elderly, successful commercialization could significantly enhance revenue streams within the next 1-2 years.
- Growth opportunity 2: The company's ongoing development of ABNCoV2, which has completed Phase II trials for SARS-CoV-2, positions it to tap into the expanding market for COVID-19 vaccines. Given the ongoing demand for booster shots and variant-specific vaccines, this could lead to substantial revenue opportunities in the next 1-3 years.
- Growth opportunity 3: Bavarian Nordic's collaboration with AdaptVac for developing new vaccines could yield additional products targeting infectious diseases. This partnership enhances R&D capabilities and could lead to market entries in emerging vaccine sectors over the next 3-5 years.
- Growth opportunity 4: The company’s focus on cancer vaccines, particularly TAEK-VAC, which is in Phase I/II trials, opens avenues in the oncology market. The global cancer vaccine market is projected to grow significantly, with potential revenues from this segment expected to materialize within 3-5 years.
- Growth opportunity 5: Expansion into new geographic markets, particularly in Asia and Africa, where vaccine demand is rising due to public health initiatives, could enhance Bavarian Nordic's global footprint. This strategy could lead to increased sales and partnerships with governments and NGOs over the next 2-4 years.
What Opportunities Does BVNKF Have?
- Expanding vaccine market driven by increased global health awareness.
- Potential for new product development through strategic partnerships.
- Growing demand for vaccines in emerging markets presents new revenue streams.
What Threats Does BVNKF Face?
- Intense competition from larger pharmaceutical companies with greater resources.
- Regulatory challenges and potential delays in product approvals.
- Market volatility and changes in government healthcare policies affecting funding.
What Are BVNKF's Competitive Advantages?
- Strong intellectual property portfolio protecting vaccine formulations and technologies.
- Established reputation and trust in the vaccine market, particularly for smallpox and monkeypox.
- Robust pipeline of innovative vaccine candidates addressing unmet medical needs.
- Strategic partnerships with leading health organizations and research institutions.
- Operational expertise in vaccine development and manufacturing processes.
What Does BVNKF Do?
Founded in 1992 and headquartered in Hellerup, Denmark, Bavarian Nordic A/S has established itself as a leader in the biotechnology sector, particularly in the development of life-saving vaccines. The company initially focused on smallpox vaccines and has since expanded its product offerings to include vaccines for monkeypox, rabies, tick-borne encephalitis, and Ebola. Its flagship products, IMVAMUNE, IMVANEX, and JYNNEOS, are non-replicating vaccines that have been pivotal in addressing public health threats. Bavarian Nordic has made significant strides in clinical research, with several candidates in various stages of development, including MVA-BN for smallpox and MVA-BN RSV for respiratory syncytial virus, both of which have reached Phase III clinical trials. The company also has promising candidates like ABNCoV2, which targets SARS-CoV-2, and TAEK-VAC, aimed at treating advanced cancers. With a strong international presence, Bavarian Nordic operates in multiple countries, including the United States, Belgium, Germany, and Japan, and has formed strategic collaborations with entities like the National Cancer Institute and AdaptVac. This extensive network and diverse product pipeline position Bavarian Nordic as a formidable player in the global biotechnology landscape.
What Products and Services Does BVNKF Offer?
- Develops and manufactures life-saving vaccines for various infectious diseases.
- Offers non-replicating vaccines for smallpox and monkeypox under the IMVAMUNE, IMVANEX, and JYNNEOS brands.
- Provides rabies vaccine for human use under the Rabipur/RabAvert name.
- Produces tick-borne encephalitis vaccine marketed as Encepur.
- Develops an Ebola vaccine known as MVABEA.
- Engages in clinical trials for innovative vaccines targeting RSV and SARS-CoV-2.
How Does BVNKF Make Money?
- Generates revenue through the sale of vaccines to healthcare providers and governments.
- Engages in licensing agreements and collaborations with research institutions and pharmaceutical companies.
- Invests in R&D to develop new vaccines, enhancing its product pipeline and market offerings.
- Leverages government contracts for vaccine supply, especially during public health emergencies.
- Utilizes strategic partnerships to expand its reach and capabilities in vaccine development.
What Industry Does BVNKF Operate In?
The biotechnology industry is experiencing rapid growth, driven by increasing demand for innovative therapies and vaccines, particularly in the wake of global health crises. The global vaccine market is projected to reach approximately $100 billion by 2026, with significant investments in research and development. Bavarian Nordic A/S is well-positioned within this landscape, focusing on niche areas such as non-replicating viral vector vaccines. The competitive landscape includes major players like Moderna and Pfizer, but Bavarian Nordic differentiates itself through its specialized vaccine offerings and established partnerships with health organizations.
Who Are BVNKF's Key Customers?
- Governments and public health organizations seeking vaccines for national immunization programs.
- Healthcare providers and hospitals requiring vaccines for patient care.
- Research institutions and pharmaceutical companies for collaborative development efforts.
- International health agencies involved in disease outbreak response.
- Private sector organizations focused on employee health and safety.
Bavarian Nordic A/S Financial Trajectory
Bavarian Nordic A/S (BVNKF) reported $1.06B in revenue for Q1 2026, a decline of 24.8% compared to the prior quarter. The company recorded net income of $17.0M, with diluted EPS of $0.22. Revenue has contracted over three consecutive quarters, which investors in this mid-cap Healthcare stock should monitor closely. Across the four most recent quarters, BVNKF averaged $3.65 in diluted EPS.
Company Profile
Bavarian Nordic A/S operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Hellerup, DK. The company is led by CEO Paul John Chaplin. BVNKF has traded publicly since 2010.
How Bavarian Nordic A/S Is Valued
Bavarian Nordic A/S carries a market capitalization of $2.14B, placing it in the mid-cap category. Relative to its peer group, BVNKF's quantitative score of 52/100 is below the peer average of 74/100.
ROE 9%Key Financial Metrics
Return on equity for Bavarian Nordic A/S stands at 9.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 8.3%, showing how much profit it generates from its asset base. BVNKF trades at a trailing price-to-earnings ratio of 11.70, below the Healthcare sector average of ~23x. Its free cash flow yield is 10.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.47 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 8.5%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 7/9Financial Health
Bavarian Nordic A/S's Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 8.28 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project Bavarian Nordic A/S revenue of about $5.51B for fiscal 2026, with EPS near $10.71. The estimate reflects 3 contributing analysts.
BVNKF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that executives believe in the potential for growth.
- Community sentiment has turned positive, with discussions highlighting Bavarian Nordic's innovative vaccine development as a game changer in the biotech sector.
- The company has received favorable attention for its advancements in infectious disease treatments, resonating well with healthcare investors.
- Recent partnerships and collaborations have bolstered the company's credibility, creating optimism around future revenue streams.
Bear Case
- Despite positive developments, some analysts express caution due to the competitive landscape in the biotech industry, which may hinder market share growth.
- Community sentiment also reflects concerns about regulatory challenges that could delay product approvals, impacting timelines.
- Market perception has been tempered by broader economic uncertainties, leading to skepticism about funding and investment in biotech sectors.
- Recent earnings reports have not met the high expectations set by the market, leading to doubts about the company's short-term performance.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.06B | $17M | $0.22 |
| Q4 2025 | $1.41B | -$298M | -$3.82 |
| Q3 2025 | $1.79B | $1.09B | $13.70 |
| Q2 2025 | $1.65B | $363M | $4.50 |
Based on FMP financials and quantitative analysis
BVNKF Latest News
No recent news available for BVNKF.
BVNKF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BVNKF.
Price Targets
Wall Street price target analysis for BVNKF.
BVNKF MoonshotScore
What does this score mean?
The MoonshotScore rates BVNKF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Paul John Chaplin
President and CEO
Paul John Chaplin has been at the helm of Bavarian Nordic A/S since 2015, bringing over two decades of experience in the biopharmaceutical industry. He holds a degree in pharmacy and has held various leadership roles in prominent pharmaceutical companies, focusing on vaccine development and commercialization.
Track Record: Under Chaplin's leadership, Bavarian Nordic has successfully advanced its vaccine candidates through clinical trials, significantly expanding its product pipeline and securing strategic partnerships that enhance the company's market position.
BVNKF OTC Market Information
The OTC Other tier includes companies that trade on the over-the-counter market but do not meet the more stringent requirements of the NYSE or NASDAQ. This tier often includes smaller companies and may have less liquidity compared to larger exchanges.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity may impact the ability to buy or sell shares quickly.
- Potential for higher volatility compared to stocks on major exchanges.
- Less stringent reporting requirements could lead to less transparency.
- Verify the company's financial health through recent earnings reports.
- Assess the status of clinical trials and product pipeline developments.
- Review any recent news or press releases regarding partnerships or contracts.
- Examine the competitive landscape and market positioning.
- Consider the potential regulatory risks associated with vaccine approvals.
- Established track record in vaccine development with multiple approved products.
- Partnerships with reputable health organizations and government entities.
- Transparent communication of clinical trial results and corporate developments.
What Investors Ask About Bavarian Nordic A/S (BVNKF) — Healthcare
What does Bavarian Nordic A/S do?
Bavarian Nordic A/S is a biotechnology company that specializes in developing and commercializing vaccines for infectious diseases. The company’s product portfolio includes vaccines for smallpox, monkeypox, rabies, tick-borne encephalitis, and Ebola, along with several candidates in clinical trials targeting other diseases. With a focus on innovative vaccine solutions, Bavarian Nordic aims to address significant public health challenges globally.
What is Bavarian Nordic A/S's drug pipeline status?
Bavarian Nordic A/S has a robust drug pipeline featuring several vaccine candidates at various stages of development. Currently, its MVA-BN RSV vaccine is in Phase III trials, targeting respiratory syncytial virus, while MVA-BN for smallpox has also reached Phase III. Additionally, ABNCoV2 has completed Phase II trials for SARS-CoV-2, and TAEK-VAC is in Phase I/II trials for advanced cancers, indicating a strong commitment to addressing unmet medical needs.
What are the main risks for BVNKF?
Bavarian Nordic A/S faces several risks, including regulatory challenges that could delay product approvals, particularly for its vaccine candidates. The company also experiences ongoing competition from larger pharmaceutical firms that have more extensive resources and established market presence. Additionally, its reliance on government contracts for revenue poses a risk if funding priorities shift or if there are changes in public health policy.
What are the key factors to evaluate for BVNKF?
Bavarian Nordic A/S (BVNKF) holds an AI score of 52/100 (moderate). Not financial advice.
How frequently does BVNKF data refresh on this page?
BVNKF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven BVNKF's recent stock price performance?
Bavarian Nordic A/S (BVNKF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio addressing critical public health needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BVNKF overvalued or undervalued right now?
Valuing Bavarian Nordic A/S (BVNKF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying BVNKF?
Before investing in Bavarian Nordic A/S (BVNKF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- All financial data is based on the latest available reports and company disclosures.